TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen Ø
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com
AntiAnthra ApS transferring shares to Prospero Limited
- Notification pursuant to section 28a of the Danish Securities Trading Act -
Copenhagen, Denmark - 17 December 2007 - Pursuant to section 28a of the Danish
Securities Trading Act, TopoTarget (OMX: TOPO) hereby reports that on 16
December 2007, one of the owners of AntiAnthra ApS transferred, a total of
205,000 TopoTarget shares (ISIN DK0060086072) from AntiAnthra ApS to another
company; Prospero Limited.
AntiAnthra ApS is a company which is a related party to Peter Buhl Jensen, the
Chief Executive Officer of TopoTarget A/S, and to Maxwell Sehested, the Chief
Scientific Officer of TopoTarget A/S.
The reported transaction consisted of a transfer from AntiAnthra, to a third
shareholder of AntiAnthra ApS namely Prospero Limited. In connection with the
transfer, the said shareholder will cease to be a shareholder of AntiAnthra
ApS.
Despite the fact that the transaction is legally comprised by Section 28a of
the Danish Securities Trading Act, it is noted that Peter Buhl Jensen and
Maxwell Sehested directly and indirectly own the same number of shares in
TopoTarget A/S as before the transaction. The market value of the transferred
shares totals DKK 4,202,500.
As the transaction was a transfer only it is not applicable to state a relevant
market.
TopoTarget A/S
For further information, please contact:
Dr. Peter Buhl Jensen Telephone +45 39 17 83 41
Chief Executive Officer Mobile +45 21 60 89 22
Background information
About TopoTarget
TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with
subsidiaries in the US, Switzerland, Germany and the UK, dedicated to finding
''Answers for Cancer'' and developing improved cancer therapies. TopoTarget is
founded and run by clinical cancer specialists and combines years of hands-on
clinical experience with in-depth understanding of the molecular mechanisms of
cancer. Focus lies on highly predictive cancer models and key cancer targets
(including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors) and a
strong development foundation has been built. TopoTarget has a broad portfolio
of small molecule pre-clinical drug candidates and nine drugs (both small
molecules and protein based) are in clinical development, including both novel
anti-cancer therapeutics and new cancer indications for existing drugs.
Savene™/Totect™ was approved by EMEA in 2006 and the FDA in 2007 and is
TopoTarget's first product on the market. For more information, please refer to
www.topotarget.com.
TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. TopoTarget cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; TopoTarget's history of
incurring losses and the uncertainty of achieving profitability; TopoTarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against TopoTarget's products, processes and
technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.
